Drug Trial Radar · NCT07873671
A Trial of RLX-2508-102 in Healthy Volunteers
Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
101
Planned (sponsor's estimate)
Start
Nov 15, 2026
Primary completion
Jan 30, 2029
Study completion Jan 30, 2029
Sponsor
- Lead sponsor
- Atridia Pty Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 14, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 64 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess safety, PK and immunogenicity profile of a single dose and multiple dose of RLX-2508 in healthy participants across different ethnic backgrounds.
Conditions
- Influenza
Interventions
RLX-2508Drug
Single dose RLX-2508 /placebo given subcutaneously - Dose level 1
RLX-2508Drug
Single dose RLX-2508 /placebo given subcutaneously - Dose level 2
RLX-2508Drug
Repeated dose of RLX-2508 /placebo given subcutaneously - Dose level 3
RLX-2508Drug
Single dose of RLX-2508 /placebo given subcutaneously - Dose level 3
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability Based on Incidence and Severity of Treatment Emergent Adverse EventsTime frame: Day 360 & Day 450
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Nucleus Network Sydney
Sydney, New South Wales, Australia
Nucleus Network Brisbane
Brisbane, Queensland, Australia
Nucleus Network Melbourne
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.